Current Licensing
Opportunities
Curated deals available through the BioRich International network. Request details on any opportunity — our team will follow up within 1–2 business days.
HER2-targeted ADC
Novel HER2-targeted antibody-drug conjugate with differentiated linker-payload technology. Phase I dose-escalation complete; favorable tolerability profile demonstrated in first two cohorts.
Oral GLP-1 Receptor Agonist
Once-daily oral GLP-1 receptor agonist in Phase II for type 2 diabetes and obesity. Strong Phase I PK/PD data. Seeking North American commercialization partner.
Enzyme Replacement Therapy
Recombinant enzyme replacement therapy for lysosomal storage disorder. Phase II completed with statistically significant primary endpoint. Regulatory path to NDA/BLA well defined.
IL-17A/F Bispecific Antibody
Bispecific antibody co-targeting IL-17A and IL-17F for moderate-to-severe psoriasis and psoriatic arthritis. Phase I safety and tolerability data available.
4th Generation CAR-T
Next-generation armored CAR-T cell therapy for relapsed/refractory multiple myeloma. Phase I/II enrollment ongoing; early efficacy signals reported.
NLRP3 Inflammasome Inhibitor
Selective NLRP3 inflammasome inhibitor with brain-penetrant properties. In vivo efficacy in Alzheimer's and Parkinson's disease models. Seeking IND-enabling study partner or full licensee.
KRAS G12C Inhibitor
Chinese pharmaceutical company seeking in-licensing rights for an approved or Phase III KRAS G12C inhibitor for the China market. Strong commercial infrastructure; full regulatory support.
PCSK9 Monoclonal Antibody
Established Chinese cardiovascular specialty company seeking in-licensing rights to an approved or late-stage PCSK9 inhibitor. Proven commercial team in tier 1 and tier 2 cities.
KRAS G12V Inhibitor
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
US/EU buyer disease-area mandate for ANCA-associated vasculitis (GPA, MPA, EGPA). Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
US/EU buyer seeking to in-license novel, potentially disease-modifying therapies for rare and special movement disorders, motor neuron disease, and rare epilepsy. Projects at any stage and modality considered; ex-China / global rights preferred.
TRAIL Agonist
US/EU buyer seeking to in-license TRAIL-agonist programs from PCC through Phase II; indication flexible. Ex-China / global rights preferred.
siRNA / Antisense Oligonucleotide
Well-established US/EU fund seeking siRNA, antisense oligonucleotide, and small-nucleic-acid programs across any disease area; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license cardiovascular and kidney disease programs across modalities (small molecule, large molecule, siRNA, peptide, antisense); preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Polycythemia Vera. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Von Willebrand Disease. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Warm Autoimmune Hemolytic Anemia. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
Energy expenditure / metabolic (non-appetite-suppression)
US/EU buyer seeking to in-license small-molecule weight-loss programs, oral formulations preferred, that drive weight loss by boosting energy metabolism or energy expenditure rather than traditional appetite-suppression mechanisms. Preclinical acceptable. Ex-China / global rights preferred.
CHRM4 Inhibitor
US/EU buyer target-interest mandate for CHRM4 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
COX / 5-LOX Inhibitor
US/EU buyer target-interest mandate for COX / 5-LOX Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
FcRn Inhibitor
US/EU buyer target-interest mandate for FcRn Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
IFN-gamma Inhibitor
US/EU buyer target-interest mandate for IFN-gamma Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAK2 V617F Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for JAK2 V617F Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
LNK Inhibitor
US/EU buyer target-interest mandate for LNK Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
AKT1 Inhibitor
US/EU buyer target-interest mandate for AKT1 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
APJ Antagonist
US/EU buyer target-interest mandate for APJ Antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
BMP9 Recombinant Protein (mimic endogenous BMP9)
US/EU buyer target-interest mandate for BMP9 Recombinant Protein (mimic endogenous BMP9) programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
CALR Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for CALR Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Matriptase-2 Inhibitor
US/EU buyer target-interest mandate for Matriptase-2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Plasminogen Inhibitor
US/EU buyer target-interest mandate for Plasminogen Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Protein S Inhibitor
US/EU buyer target-interest mandate for Protein S Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
SF3B1 Splicing Modulator
US/EU buyer target-interest mandate for SF3B1 Splicing Modulator programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TIE2 Inhibitor
US/EU buyer target-interest mandate for TIE2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TPO Receptor / MPL Inhibitor
US/EU buyer target-interest mandate for TPO Receptor / MPL Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Oral / Cyclic Peptides
US/EU buyer mandate to in-license oral peptide and cyclic peptide programs. No restriction on development stage or indication. Ex-China / global rights preferred.
Mutant CALR (Calreticulin)
US/EU buyer mandate to in-license programs targeting mutant CALR (calreticulin) for hematologic malignancies. Open to small molecule, biologic, or siRNA modalities; preclinical stage acceptable. Ex-China / global rights preferred.
Don't see what you're looking for? We have additional opportunities not listed publicly.
Discuss your criteria with our team